Michael Heuser
A5053578678- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Retinoids in leukemia and cellular processes
- Histone Deacetylase Inhibitors Research
- Hematopoietic Stem Cell Transplantation
- Multiple Myeloma Research and Treatments
- Epigenetics and DNA Methylation
- CAR-T cell therapy research
- Hedgehog Signaling Pathway Studies
- RNA Interference and Gene Delivery
- Immune Cell Function and Interaction
- MicroRNA in disease regulation
- Phagocytosis and Immune Regulation
- Blood disorders and treatments
- Advanced biosensing and bioanalysis techniques
- RNA Research and Splicing
- Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Sarcoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
Medizinische Hochschule Hannover
2016-2025
Martin Luther University Halle-Wittenberg
2024-2025
Leibniz Institute for Plasma Science and Technology
2025
University Hospital in Halle
2024
Intelligent Transport Systems Niedersachsen
2023
RWTH Aachen University
2023
Kantonsspital Aarau
2023
University of Freiburg
2009-2022
University Medical Center Freiburg
2022
Max Planck Institute for Comparative and International Private Law
2019
Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology AML and informs clinical practice.
65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic
BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters cytogenetic abnormalities. Somatic gene mutations not yet used in risk of patients with MDS. METHODS: To develop a clinical-molecular prognostic model (IPSS-Molecular [IPSS-M]), pretreatment diagnostic or peridiagnostic samples from 2957 MDS were profiled 152 genes. Clinical...
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization harmonization of ongoing manner has updated the 2018 ELN recommendations based on significant developments field. New revised were established during in-person online meetings, a 2-stage Delphi poll was conducted to optimize consensus. All are...
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. 100 mg (oral, QD) was administered continuously 28-day cycles; LDAC 20 (subcutaneous, BID) 10 per 28 days. Patients (stratified by cytogenetic risk) were randomized (2:1)...
To study the incidence and prognostic impact of mutations in DNA methyltransferase 3A (DNMT3A) patients with acute myeloid leukemia.A total 489 AML were examined for DNMT3A by direct sequencing. The was evaluated context other clinical markers genetic risk factors (cytogenetic group; NPM1, FLT3, CEBPA, IDH1, IDH2, MLL1, NRAS, WT1, WT1 SNPrs16754; expression levels BAALC, ERG, EVI1, MLL5, MN1, WT1).DNMT3A found 87 (17.8%) who younger than 60 years age. Patients older, had higher WBC platelet...
The combination of ivosidenib - an inhibitor mutant isocitrate dehydrogenase 1 (IDH1) and azacitidine showed encouraging clinical activity in a phase 1b trial involving patients with newly diagnosed IDH1-mutated acute myeloid leukemia.In this 3 trial, we randomly assigned leukemia who were ineligible for intensive induction chemotherapy to receive oral (500 mg once daily) subcutaneous or intravenous (75 per square meter body-surface area 7 days 28-day cycles) matched placebo azacitidine....
Purpose To study the incidence and prognostic impact of mutations in Additional sex comb-like 1 (ASXL1) a large cohort patients with myelodysplastic syndrome (MDS). Patients, Materials, Methods Overall, 193 MDS 65 healthy volunteers were examined for ASXL1 by direct sequencing expression levels ASXL1. The mutation was evaluated context other clinical molecular markers. Results Mutations occurred frequency 20.7% (n = 40 193) 70% 28) being frameshift 30% 12) heterozygous point leading to...
Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which highly adverse prognostic marker. However, CK-MDS can carry wide range chromosomal abnormalities and somatic mutations. To refine risk patients, we examined data from 359 shared by International Working Group for MDS. Mutations were underrepresented exception TP53 mutations, identified 55%...
Clonal hematopoiesis of indeterminate potential (CHIP) occurs in the blood approximately 20% older persons. CHIP is linked to an increased risk hematologic malignancies and all-cause mortality; thus, eligibility stem-cell donors with questionable. We comprehensively investigated how donor affects outcome allogeneic hematopoietic transplantation (HSCT).We collected samples from 500 healthy, related HSCT (age ≥ 55 years) at time donation for targeted sequencing a 66-gene panel. The effect was...
Diabetic nephropathy is the main cause of end-stage renal disease. MicroRNAs are powerful regulators genome, and global expression profiling revealed miR-21 to be among most highly regulated microRNAs in kidneys mice with diabetic nephropathy. In kidney biopsies patients, correlated tubulointerstitial injury. situ PCR analysis showed a specific enrichment glomerular cells. We identified cell division cycle 25a (Cdc25a) cyclin-dependent kinase 6 (Cdk6) as novel targets mesangial...